• 1
    Sherlock S, Dooley J. Malignant liver tumors. In: SherlockS, DooleyJ, editors. Disease of the liver and biliary system. Oxford: Blackwell Science, 2002: 537561.
  • 2
    The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 1994; 74: 27722780.
  • 3
    Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood. 1999; 93: 17981808.
  • 4
    Shearer MJ. The roles of vitamin D and vitamin K in bone health and osteoporosis prevention. Proc Nutr Soc. 1997; 56: 915937.
  • 5
    Chlebowski RT, Dietrich M, Akman S, Block JB. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep. 1985; 69: 527532.
  • 6
    Nishikawa Y, Carr BI, Wang M, et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J Biol Chem. 1995; 270: 2830428310.
  • 7
    Sakai I, Hashimoto S, Yoda M, et al. Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun. 1994; 205: 13051310.
  • 8
    Wu FYH, Liao WC, Chang HM. Comparison of antitumor activity of vitamins K1, K2, K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci. 1993; 52: 17971804.
  • 9
    Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology. 1995; 22: 876882.
  • 10
    Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol. 1999; 69: 2426.
  • 11
    Liebman HA, Furie BC, Tong M, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310: 14271431.
  • 12
    Nakagawa T, Seki T, Shiro T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol. 1999; 14: 281286.
  • 13
    Koike Y, Shiratori Y, Sato S, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. A prospective analysis of 227 patients. Cancer. 2001; 91: 561569.
  • 14
    Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H. Changes of plasma des-γ-carboxy-prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer. 1992; 69: 3138.
  • 15
    Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab. 1998; 16: 106112.
  • 16
    Bruix J, Sherman M, Llvet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421430.
  • 17
    Bouzahazah B, Nishikawa Y, Simon D, Carr BI. Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol. 1995; 165: 459467.
  • 18
    Ohizumi H, Masuda Y, Nakajo S, Sakai I, Ohsawa S, Nakaya K. Geranylgeraniol is a potent inducer of apoptosis in tumor cells. J Biochem. 1995; 117: 1113.
  • 18
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999; 131: 174181.
  • 20
    Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med. 2001; 134: 963967.
  • 21
    Muto Y, Moriwaki H, Ninomiya M, et al. The Hepatoma Prevention Study Group. Prevention of second primary tumor by an acyclic retinoid, polyrenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 1996; 334: 15611567.